Related Experiment Video

Updated: Sep 22, 2026

Protocols for Vaginal Inoculation and Sample Collection in the Experimental Mouse Model of Candida vaginitis
07:57

Protocols for Vaginal Inoculation and Sample Collection in the Experimental Mouse Model of Candida vaginitis

Published on: December 8, 2011

Imidazoles for vaginitis

C R Lee1, C A McKenzie, A Nobles

  • 1Department of Pharmacy Practice, Campbell University School of Pharmacy, Buies Creek, N.C.

American Pharmacy
|July 1, 1991
PubMed

Insights

Over-the-counter clotrimazole and miconazole are now effective treatments for vaginal candidiasis. These imidazole antifungals offer improved patient compliance due to shorter regimens and greater efficacy compared to older therapies.

Area of Science:

  • Mycology
  • Pharmacology
  • Women's Health

Background:

  • Vaginal candidiasis is a prevalent fungal infection affecting women.
  • Several therapeutic agents exist for treating this condition.
  • Clotrimazole and miconazole, introduced in 1975, are now available over-the-counter (OTC).

Purpose of the Study:

  • To review the efficacy and availability of current treatments for vaginal candidiasis.
  • To highlight the shift in therapeutic preference towards imidazole agents.
  • To inform about the cost-effectiveness of OTC antifungal regimens.

Main Methods:

  • Literature review of antifungal agents for vaginal candidiasis.
  • Comparison of imidazole agents (clotrimazole, miconazole) with nystatin.
  • Analysis of treatment regimen duration and patient compliance factors.

Main Results:

  • Imidazole agents demonstrate greater antifungal activity than nystatin.
  • Shorter treatment regimens enhance patient compliance.
  • OTC imidazole regimens range from $12.00 to $24.00.

Conclusions:

  • Clotrimazole and miconazole have become primary therapies for vaginal candidiasis.
  • The availability of these agents over-the-counter improves accessibility.
  • Imidazole antifungals offer advantages in efficacy and patient compliance.

More Related Videos

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms06:50

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms

Published on: September 16, 2022

Modeling Healthy and Dysbiotic Vaginal Microenvironments in a Human Vagina-on-a-Chip08:15

Modeling Healthy and Dysbiotic Vaginal Microenvironments in a Human Vagina-on-a-Chip

Published on: February 16, 2024

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Trichomoniasis01:18

Trichomoniasis

Trichomonas vaginalis is a flagellated protozoan parasite and the causative agent of trichomoniasis, one of the most prevalent non-viral sexually transmitted infections in the United States. This extracellular parasite primarily colonizes the lower genitourinary tract in women—particularly the vagina—and in men, the urethra and prostate. Its structural and functional adaptations enable its survival, motility, and pathogenicity within the host environment.Structural Features and Host EntryT.
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...